Showing 1531-1540 of 2314 results for "".
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- Atsena Therapeutics Initiates Dosing in Second Cohort of Phase 1/2 Trial Evaluating XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-initiates-dosing-in-second-cohort-of-phase-12-trial-evaluating-xlrs-gene-therapy/2482162/Dosing has been initiated in the second cohort of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS), according to Atsena Therapeutics. ATSN-201, a gene therapy product candidate,
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- DigitalOptometrics Launches DOT Translation Servicehttps://modernod.com/news/digitaloptometrics-launches-dot-translation-service/2482073/DigitalOptometrics announced the launch of “DOT” (DigitalOptometrics Translate), a new translation service that aims to improve patient care. “DOT” is a real-time translation technology that breaks language barriers, allowing eye care professionals to commun
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Aurion Biotech Announces First Subject Dosed in US Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-subject-dosed-in-us-phase-1-2-clinical-trial/2481908/Aurion Biotech announced that it has dosed the first subject in its phase 1/2 US clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “On the heels of our recent approval in Japan, we ar
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el